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Aim To determine the frequency and the characteristics 
of cutaneous manifestations, especially vitiligo and alo-
pecia areata, in patients with chronic graft-vs-host disease 
(cGVHD).
Methods 50 patients with cGVHD were prospectively en-
rolled in the observational study protocol and evaluated by 
an experienced dermatologist. The evaluation was focused 
on the clinical spectrum of skin and adnexal involvement, 
and the cutaneous GVHD score was determined accord-
ing to National Institutes of Health (NIH) Consensus criteria. 
The presence of vitiligo, alopecia, xerosis, nail changes, and 
dyspigmentation was also assessed.
Results Out of 50 cGVHD patients, 28 (56%) had skin in-
volvement, and 27 of them (96%) had hypo and/or hyper-
pigmentations. 11 patients (39%) had a mild cutaneous NIH 
cGVHD score, 22% moderate, and 39% severe. 15 (30%) pa-
tients had nail changes and 10 (20%) had vitiligo or alope-
cia areata. Univariate analysis showed that patients with vi-
tiligo/alopecia areata received more lines of prior systemic 
immunosuppressive therapy (P = 0.043), had lower Karnof-
sky performance status (P = 0.028), and had a higher B-cell 
number (P = 0.005), platelet count (P = 0.022), and total pro-
tein (P = 0.024). Vitiligo and alopecia areata were associated 
with higher NIH skin score (P = 0.001), higher intensity of 
immunosuppressive treatment (P = 0.020), and total body 
irradiation conditioning (P = 0.040). Multivariate regression 
model showed that patients with higher NIH skin scoring 
were 3.67 times more likely to have alopecia and/or vitiligo 
(odds ratio 3.67; 95% confidence interval 1.26-10.73), con-
trolled for all other factors in the model (age at study entry, 
number of B-cells, platelet count, and global NIH score).
Conclusion These data indicate that vitiligo and alopecia 
areata occur more frequently in cGVHD than previously re-
ported.
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Graft-vs-host disease (GVHD) is a complex multi-organ dis-
ease that occurs in patients after allogeneic hematopoietic 
stem cell transplantation (allo-HSCT) (1). Based on the con-
sensus recommendations of the GVHD working group of 
the US National Institutes of Health (NIH), GVHD may be 
divided into classic acute GVHD, persistent, recurrent or 
delayed-onset acute GVHD, and classic chronic GVHD and 
overlap chronic GVHD (2).
At the time of the initial chronic GVHD (cGVHD) diagnosis, 
most commonly involved organ system is the skin, in ap-
proximately 75% of patients, followed by, in decreasing fre-
quency, the oral mucosa, liver, and eye (3,4). Chronic GVHD 
may affect various skin compartments –the epidermis, 
dermis, and subcutis (1). Diagnostic skin manifestations of 
cGVHD are poikiloderma, lichen planus-like eruptions, li-
chen-sclerosus-like lesions, morphea-like sclerosis, and 
deep sclerosis/fasciitis and therefore there is no need for a 
biopsy to establish the diagnosis (2). Although these chang-
es are usually readily evaluated by an experienced derma-
tologist, differential diagnoses may be necessary. If there is 
uncertainty, a biopsy should be performed (1). Consensus 
on performing skin biopsies in suspected cGVHD was pub-
lished by Hillen et al (5). Among less typical manifestations 
of cGVHD are ichthyosiform presentations, depigmenta-
tion, follicular erythematous papules resembling keratosis 
pillars, psoriasisform plaques, and annular erythematous 
lesions (1). Sometimes, there is involvement of the scalp, 
which may present as scarring or nonscarring alopecia. Var-
ious nail changes, including thinning of the nail plate, nail 
dystrophy with longitudinal ridging, or complete loss of the 
nail are often found among patients with cGVHD.
Chronic GVHD is known to be associated with dysregulation 
of the host immune system and could act as a triggering fac-
tor for the appearance of autoimmune diseases such as viti-
ligo and alopecia areata (6). However, reports on vitiligo and 
alopecia areata in chronic GVHD studies are exceptionally 
rare, and mostly are case studies. Therefore, the aim of this 
study was to determine the frequency and characteristics of 
dermatological manifestations, with an emphasis on vitiligo 
and alopecia areata, in a well characterized prospectively in-
cepted study cohort of Croatian patients with cGVHD.
PaTIENTS aND METhoDS
Study cohort
This study is a part of the protocol entitled “Clinical and 
Biological Factors Determining Severity and Activity 
of Chronic Graft-Versus-Host Disease After Allogeneic He-
matopoietic Stem Cell Transplantation.” Patients were pro-
spectively enrolled into the study at the University Hospital 
Center Zagreb from June 2013 to December 2015 and eval-
uated for cGVHD by a multidisciplinary team of subspecial-
ists in hematology, dermatology, dentistry, ophthalmology, 
physical therapy, gynecology, neurology, and other special-
ist if needed. 45 adults and 5 pediatric patients were evalu-
ated and diagnosed with cGVHD according to the 2005 NIH 
Consensus criteria (2). Laboratory workup was done and 
quality of life questionnaires were filled out at the study en-
try. All patients signed informed consent approved by the 
Ethical Committee of the University Hospital Center Zagreb.
Dermatologic evaluation
Dermatologic evaluation was focused on determining the 
cutaneous GVHD score according to NIH criteria, assessment 
of other objective clinical parameters including the presence 
of vitiligo, xerosis, alopecia, nail changes, and dyspigmenta-
tion. During the evaluation of skin changes, the Cutaneous 
GVHD Assessment Worksheet was completed, and the Total 
Dermatology Score was tallied (7). Skin involvement was de-
termined by the scoring system according to the 2005 Na-
tional Institutes of Health (NIH) Consensus Criteria (2). Skin 
disease severity was divided into levels ranging from 0 to 3 
based on the features and the extent of involvement. Extent 
(% body surface area, BSA) of involvement was estimated for 
lichenoid, sclerotic, fascial disease, and/or regions with bul-
lae, erosions, or ulcers. A score of 0-3 (none, mild, moderate, 
severe) was given, which directly corresponds to BSA affect-
ed. The NIH scores were categorized as mild (1-2 organs with 
a score 1), moderate (≥3 organs with a score 1, any organ 
with a score of 2, or a lung with a score of 1), and severe (any 
organ with a score of 3 or a lung with a score ≥2). The scor-
ing was performed by an experienced dermatologist. Skin 
biopsy was performed in all patients who had skin changes 
according to recommendations for skin biopsy use in clinical 
trials (6). In non-sclerotic GVHD, a 4-mm punch biopsy pen-
etrating the subcutaneous adipose tissue was performed. In 
patients with sclerotic GVHD, a scalpel biopsy reaching the 
deep subcutis and, if necessary the fascia, was performed. 
Each patient was examined for skin tumors and pigmented 
lesions (nevi). Subjective symptoms, including pruritus, pain, 
and edema, were also evaluated.
Statistical analysis
According to the results of Kolmogorov-Smirnov test and 
the small number of participants, appropriate non-para-
231Čeović et al: Vitiligo and alopecia areata in chronic graft-versus-host disease
www.cmj.hr
metric tests were used in all analyses. Categorical variables 
are shown as frequencies and corresponding percentages, 
and quantitative variables as medians and ranges. Fisher 
exact test or Fisher-Freeman-Halton exact test of indepen-
dence when the contingency table was larger than 2 × 2 
was used to analyze differences in categorical clinical pa-
rameters between patients (GVHD patients with alopecia 
areata and/or vitiligo) and controls (GVHD patients without 
alopecia areata and/or vitiligo) and Mann-Whitney U test 
was used to analyze the differences in quantitative vari-
ables. Binary logistic regression was performed to assess 
the impact of a number of factors on the likelihood that 
patients will have alopecia and/or vitiligo. The model con-
tained four independent variables derived from previous-
ly made bivariate analyses and clinical relevance. P values 
below 0.05 were considered significant. Data analysis soft-
ware system IBM SPSS Statistics, version 21.0 (www.spss.
com, license grantee University of Zagreb, Faculty of Hu-
manities and Social Sciences) was used in statistical analy-
ses and graphical images.
RESuLTS
Patient characteristics
50 patients, 22 (44%) female, with a median age of 40 (range 
9-71) who underwent allo-HSCT and were diagnosed with 
cGVHD by the NIH Consensus criteria (2) were enrolled into 
the study and were referred to the Dermatology Depart-
ment for evaluation. Main indications for transplant were 
acute leukemia and myelodysplastic syndrome (62%) and 
myeloproliferative neoplasm (22%). 31 (62%) patients re-
ceived myeloablative conditioning and 3 patients (6%) un-
derwent total body irradiation (TBI) (Table 1). 31 patients 
(62%) received transplant from a related donor, 29 (58%) 
from a female donor, and 31 (62%) patients received pe-
ripheral blood stem cell as a cell source. 36 patients (72%) 
had previous acute GVHD of the skin. 23 (46%) presented 
with quiescent, 14 (28%) with de novo, and 13 (26%) with 
progressive onset, and 45 patients (90%) were classified as 
classic cGVHD. The majority of the patients (50%) were re-
ceiving no immunosuppression or mild intensity immuno-
suppression (8), and 52% had active GVHD by clinical im-
pression defined as inactive off systemic therapy or topical 
immunosuppression, inactive on systemic therapy or topi-
cal immunosuppression, active irrespective of the level of 
current therapy and highly active irrespective of the lev-
el of current therapy. 3 patients (6%) had mild global NIH 
score, 20 (40%) moderate, and 27 (54%) severe global NIH 
score (Table 2).
Dermatological findings
Among 50 patients diagnosed with cGVHD, 28 (56%) had 
skin involvement. 11 patients had mild cutaneous NIH 
cGVHD score (39%), 6 had moderate (22%), and 11 patients 
(39%) had severe score. 27 (96%) patients had hypo and/or 
hyperpigmentation changes. 36 patients (72%) had a his-
tory of acute GVHD, all of whom had skin involvement at 
the time of diagnosis. In 25 of 28 (89%) patients with clini-
cal diagnostic criteria for cutaneous cGVHD, skin biopsy 
was performed and histological diagnosis of cGVHD was 
established. In 3 of 28 patients skin biopsy was not per-
formed because the patients refused the biopsy. 10 pa-
tients (20%) were diagnosed with vitiligo or alopecia area-
ta; 4 of them had vitiligo (8%) and 6 (12%) had alopecia 
TaBLE 1. Demographic characteristics of the study population*
Characteristic N (%)
age
median (range)  40 (9-71)
Patient sex
female  22 (44)
male  28 (56)
Sex of the donor
female  29 (58)
male  18 (36)
unknown   3 (6)
Diagnosis
AML, ALL, MDS  31 (62)
CML, MPN  11 (22)
AA, PNH   5 (10)
NHL, HL, CLL   2 (4)
immunodeficiency   1 (2)
Stem cell source
bone marrow  19 (38)
PBSC  31 (62)
Donor relationship
related  31 (62)
unrelated  19 (38)
Conditioning regimen
myeloablative conditioning  19 (38)
reduced intensity conditioning  31 (62)
Days from transplant to cGVhD diagnosis
median (range) 288 (54-3886)
Days from cGVhD diagnosis to study enrolment
median (range) 154 (0-7125)
*aML – acute myeloid leukemia, aLL – acute lymphoblastic leukemia, 
MDS – myelodysplastic syndrome, CML – chronic myeloid leukemia, 
MPN – myeloproliferative neoplasm, aa – aplastic anemia, PNh – par-
oxysmal nocturnal hemoglobinuria, NhL – Non hodgkin lymphoma, 
hL – hodgkin lymphoma, CLL – chronic lymphocytic leukemia, PBSC 
– peripheral blood stem cell.
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areata. In the vitiligo/alopecia areata group 4 patients also 
had sclerotic cGVHD.
Nail changes were observed in 15 (30%) patients, most 
commonly longitudinal ridging, splitting, or brittleness (12 
patients). Pterygium unguis was observed in 2 patients, and 
onycholysis in 1 patient. In 1 male patient who had ophi-
asis pattern alopecia areata, pterygium was present on all 
the fingernails (Figure 1A) and toenails (Figure 1B), and in 
1 male patient who had vitiligo, it was present on a single 
fingernail (Figure 2). Ulcers and erosions were observed in 
6 patients, all of them were scored as severe cGVHD. Pru-
ritus was observed in 15 (30%) patients and skin pain in 4 
(8%) patients. 35 patients (70%) had skin xerosis.
As systemic immunosuppressive therapy is associated with 
an increased risk of cutaneous neoplasia, all patients un-
derwent evaluation for cutaneous neoplasia and nevi. We 
did not find any malignant cutaneous neoplasia and we 
diagnosed 3 atypical nevi; they were sent for a total exci-
sion, and the diagnosis was pathohistologically confirmed 
as dysplastic nevi.
Vitiligo and alopecia areata
4 patients were diagnosed with vitiligo and all of them 
had the onset after the allo-HSCT. All patients with vitili-
go were men, 2 of them had female donors (sisters), 1 had 
his brother as donor, and 1 had an unrelated HLA-matched 
donor (male). All vitiligo patients fulfilled clinical diagnostic 
criteria for cutaneous GVHD, and were histologically diag-
nosed as “consistent with GVHD” or “definitive GVHD” (1 like 
TaBLE 2. Transplant characteristics of in patients with graft-vs-
host disease (GVhD) included in the study
Characteristic N (%)
acute GVhD
yes 36 (72)
no 14 (28)
acute skin GVhD
yes 22 (44)
no 28 (56)
Chronic GVhD onset
de novo 14 (28)
progressive 13 (26)
quiescent 23 (46)
Chronic cGVhD classification
classic 45 (90)
overlap 5 (10)
Global National Institutes of health Score
mild 3 (6)
moderate 20 (40)
severe 27 (54)
Lines of prior systemic treatment
median (range) 2 (0-6)
Intensity of immunosuppression
none/mild 25 (50)
moderate 18 (36)
high 7 (14)
Chronic GVhD activity
active 26 (52)
inactive 24 (48)
FIGuRE 1. Pterygium in a patient with chronic graft-vs-host 
disease. (A) all fingernails and (B) all toenails. The image is 
published with the patient’s consent.
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sclerotic type cGVHD and 3 like lichenoid cGVHD). 2 pa-
tients with vitiligo also had leukotrichia, 1 with completely 
white eyebrows and white eyelashes and the other with 
white left eyelashes (Figure 3A), and patches of white hair 
in the beard (Figure 3B). In addition, 2 vitiligo patients also 
complained of photosensitivity.
11 patients had well developed changes in hair growth 
and in the rest of the body hair. Alopecia areata was diag-
nosed in 6 patients: 5 in the scalp (2 female children (Figure 
4A), 2 adult women and 1 adult man), and in 1 male pa-
tient, in the beard. In another male patient, the beard did 
not grow at all. 1 male patient had ophiasis pattern of alo-
pecia areata (Figure 4B). The other 4 patients had very thin 
hair. 1 female patient had lost both of her eyebrows and 
her pubic hair, but the scalp hair grew well after the trans-
plantation. 2 patients with alopecia areata received TBI as 
part of conditioning. In the group of patients with alopecia 
areata, well-defined areas of round hair loss without scar-
ring were distinguished from active skin GVHD at the site, 
persistent alopecia after recovery from chemotherapy and 
radiotherapy, scalp infections, telogen and androgen efflu-
vium, and androgenetic alopecia. Alopecia areata was dis-
tinguished from other causes of alopecia on the basis of 
medical history, by clinical and dermoscopic examination 
and microscopy (culture). 1 patient had a generalized dis-
tribution of vitiligo (Figure 5A and 5B).
Factors associated with vitiligo/alopecia areata
Univariate analysis showed that patients with vitiligo/alo-
pecia areata were younger (29 vs 44 years old, P = 0.028), 
received more lines of systemic immunosuppressive ther-
apy (P = 0.043), had lower Karnofsky performance sta-
tus (P = 0.028), had higher number of B-cells (P = 0.005), 
higher platelet count (P = 0.022), and higher total proteins 
(P = 0.024) than GVHD patients without alopecia areata 
and/or vitiligo. Vitiligo and alopecia areata were associated 
with higher NIH skin score (P = 0.001), higher intensity of 
immunosuppressive treatment (P = 0.020), and TBI condi-
FIGuRE 2. Pterygium and vitiligo in a patient with chronic 
graft-vs-host disease. The image is published with the patient’s 
consent.
FIGuRE 3. Vitiligo and leukotrichya in a patient with chronic 
graft-vs-host disease. (A) Eyebrow and eyelash; (B) beard. The 
image is published with the patient’s consent.
FIGuRE 4. alopecia areata in a patient with chronic graft-vs-
host disease. (A) Frontoparietal; (B) ophiasis. The image is 
published with the patient’s consent.
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tioning (P = 0.040) (Table 3, Table 4, Figure 6). We did not 
find any differences between patients with and without 
vitiligo/alopecia areata in terms of sex of the donor, trans-
plant cell source, prior acute GVHD, cGVHD onset, cGVHD 
classification, or organ involvement (except skin), global 
NIH score, and the majority of laboratory data (C reactive 
protein, albumins, complement components C3 and C4, 
etc), including antibodies (anticardiolipin IgG, anticardio-
lipin IgM, rheumatism factor).
Predictive factors for vitiligo/alopecia areata
Binary logistic regression model for prediction of vitiligo 
and alopecia areata included 4 independent variables (NIH 
skin score, age at study entry, number of B-cells, platelet 
count and global NIH score) derived from bivariate analy-
ses (Table 5). The full model containing all predictors was 
statistically significant, X2 (5, N = 45) = 25.45, P < 0.001, and 
explained 66.1% (Nagelkerke R2) of dependent variable 
variance, and correctly classified 93.3% of the cases, indi-
cating that the model was able to distinguish between 
GVHD patients who had from those who did not have al-
opecia and/or vitiligo. Hosmer-Lemeshow goodness of fit 
test result for this logistic regression model was non-sig-
nificant (X2 = 7.75, P = 0.355), indicating that this regression 
model is applicable. NIH skin scoring was a significant pre-
dictive factor of alopecia and/or vitiligo – for each level of 
NIH skin scoring elevation patients were 3.67 times more 
likely to have alopecia and/or vitiligo (odds ratio 3.67; 95% 
confidence interval 1.26-10.73), controlled for all other fac-
tors in the model.
DISCuSSIoN
We found a higher percentage of vitiligo and alopecia area-
ta patients than expected compared to a prior retrospec-
TaBLE 3. univariate analysis of variables associated with vitiligo or alopecia areata in patients with graft-vs-host disease (GVhD) 
included in the study
Vitiligo or alopecia areata
Negative (N = 38) Positive (N = 10)
25th 50th (median) 75th 25th 50th (median) 75th P
Age at entry (years)  28.00  44.00  53.00  18.00   29.00   36.00 0.028
Days from chronic GVHD diagnosis to enrollment  14.00 124.00 219.00 262.00 1175.50 3184.00 0.002
Lines of prior systemic therapy   0.00   1.00   2.00   1.00    3.00    4.00 0.043
Karnofsky score (%)  80.00 90.00
100.00
 70.00  80.00   90.00    0.028
B-cells (number)  84.00 167.00 361.00 312.00  553.00  886.00 0.005
Platelets ( × 109g/L) 148.00 199.00 251.00 222.00  255.50  368.00 0.022
Total proteins (g/L)  59.00  67.00  72.00  71.00   73.50   78.00 0.024
FIGuRE 5. Vitiligo-generalized distribution in a patient with chronic graft-vs-host disease. (A) Back; (B) legs. The image is published 
with the patient’s consent.
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tive report (9). Patients suffering from vitiligo and alopecia 
areata had higher NIH skin scores and clinical markers of 
immune activation, and more frequent and more severe 
nail changes than other cGVHD patients.
Vitiligo and/or alopecia areata are still considered uncom-
mon phenomena in allo-HSCT recipients, although con-
nection of vitiligo and cGVHD has already been established 
(7,9-16). Alajlan et al (7) described a patient with multiple 
myeloma in whom generalized vitiligo developed within 
3 months after allo-BMT from his HLA-matched sister with 
vitiligo, and they proposed that adoptive transfer of donor 
immunity to the recipient may play a role in the develop-
ment of vitiligo. In our study, not a single donor had viti-
ligo, and no one in the patients’ closer family suffered from 
vitiligo. Although other skin diseases, for example, psoriasis 
and allergic diathesis (eg, atopy), have also been described 
as being acquired by BMT recipients (17-19), we found no 
similar cases in our study.
Zuo et al (9) found that the risk factors for vitiligo and alo-
pecia areata were female donor to male recipient sex mis-
match and a positive test for cardiolipin antibody, and they 
identified 4.9% participants with vitiligo and 0.7% with alo-
pecia areata (9). In our study, there was a much higher per-
centage of both vitiligo (8%) and alopecia areata (12%). We 
TaBLE 4. univariate analysis of variables associated with vitiligo or alopecia areata in patients with graft-vs-host disease (GVhD) 
included in the study
Vitiligo or alopecia areata
negative positive
N % N % P
Total body irradiation conditioning no 34 100.00 7 77.80 0.00
yes  0 0.00 2 22.20
Lines of prior systemic therapy 0 12 32.40 2 22.20 0.0034
1  7 18.90 1 11.10
2 11 29.70 0 0.00
3  6 16.20 2 22.20
4  0 0.00 3 33.30
5  0 0.00 1 11.10
6  1 2.70 0 0.00
Intensity of immunosuppression (Sandy’s scale) none/mild 17 44.70 7 70.00 0.020
moderate 18 47.40 0 0.00
high  3 7.90 3 30.00
Disease activity inactive 17 44.70 8 80.00 0.075
active 21 55.30 2 20.00
Skin National Institutes of Health (NIH) score 0 21 55.30 1 10.00 0.001
1 10 26.30 1 10.00
2  4 10.50 2 20.00
3  3 7.90 6 60.00
Global NIH score mild 21 55.30 1 10.00 0.442
moderate 10 26.30 1 10.00
severe  4 10.50 2 20.00
TaBLE 5. Multivariate model for prediction of vitiligo or alopecia areata in patients with graft-vs-host disease (GVhD) included in the 
study
95% confidence interval 
odds ratio (oR) lower upper P
Age at entry 0.94 0.83  1.07 0.377
National Institutes of Health (NIH) skin scoring 3.68 1.26 10.73 0.017
B cells (number of cells) 1.00 1.00  1.01 0.091
Platelets ×109 L 1.00 0.98  1.01 0.847
Global NIH score 2.38 0.20 28.49 0.495
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also did not find an association between vitiligo/alopecia 
areata and female donors. Another study found that pa-
tients with vitiligo/alopecia areata had higher B-cell count, 
perhaps consistent with cGVHD–related autoimmunity 
(20). However, we did not find an association with the pres-
ence of antibodies (anticardiolipin IgG, anticardiolipin IgM, 
rheumatism factor). Also, in our study vitiligo and alopecia 
areata were associated with higher platelet count, which 
in previous studies was associated with more active and 
more severe disease (21) and sclerotic cGVHD (22).
Our patients manifested a variety of vitiligo presenta-
tions, the most frequent among which were the clas-
sic periorbital, perioral, and acrofacial distributions, similar 
to the findings of Zuo et al (9). The majority of patients with 
hair changes also had nail involvement, which is well-de-
scribed in patients with alopecia areata, but a link between 
ophiasis and pterygium has not been documented.
Although TBI has been associated with elevated risk of 
aGVHD and cutaneous cGVHD, to our knowledge, this is 
the first study in which an association between TBI and lat-
er development of vitiligo/alopecia areata has been found. 
However, we should interpret this result with caution, since 
there were only 2 patients who received TBI.
This study limitations are the small number of patients 
(n = 50) and the small total number of patients with specif-
ic dermatological manifestation. Despite the small number 
of patients, we think that the data presented here provide 
sufficient evidence that vitiligo and alopecia areata occur 
more frequently than has been published, and are associ-
ated with higher cGVHD severity and activity. Also, for the 
first time the Croatian patient population (an European co-
hort) with cGVHD was carefully monitored for dermatolog-
ical manifestations. Considering the increasing incidence 
of cGVHD and the renewed research focus on this topic 
(23,24), further studies are needed to determine the true 
prevalence of vitiligo and alopecia areata in cGVHD pa-
tients and help find a better treatment for these patients, 
because they are frequently psychologically and cosmeti-
cally disturbed by these skin manifestations.
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